Raymond James analyst Andrew Cooper downgrades Invitae (NYSE:NVTA) from Outperform to Market Perform.
Why Processa Pharmaceuticals (PCSA) Stock Is Skyrocketing
Processa Pharmaceuticals shares are trading higher by 36.9% during Friday's session. The company announced plans to expand the development of Next Generation Capecitabine.